Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02985398 · ClinicalTrials.gov registry record · Phase 3
An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine
A Phase 3 study, sponsored by Alder Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 128
- Enrollment target
NCT02985398: Completed Phase 3 study, sponsored by Alder Biopharmaceuticals.
NCT02985398 is a Phase 3 study that has completed, run by Alder Biopharmaceuticals. The registered enrollment target is 128 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02985398, a Phase 3 study, has completed, sponsored by Alder Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 128 participants
- Enrollment target
Study Summary
An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine
Primary Outcome
Treatment emergent adverse events were defined as adverse events with start date and time on or after the date and time of the initial study drug infusion.
Interventions
- BIOLOGICAL ALD403 (Eptinezumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2016-12 |
| Est. Completion | 2019-03 |
| Phase | Phase 3 |
What the finished NCT02985398 record still lists
NCT02985398 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which ALD403 (Eptinezumab) is the first listed.
NCT02985398 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02985398 about?
NCT02985398 is a clinical study titled "An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine". An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine
What is the current status of trial NCT02985398?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 128 participants. The study started on 2016-12. Estimated completion is 2019-03.
What interventions are being tested in trial NCT02985398?
The interventions under investigation include: ALD403 (Eptinezumab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02985398?
This trial is sponsored by Alder Biopharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02985398's enrollment target sits among peer trials
128 1601st of 2000 higher than 399 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia